Abstract: Objective To observe the efficacy and safety profile of malate sunitinib as secondline therapy for patients with advanced gastrointestinal stromal tumors（GISTs）. Methods From March 2009 to October 2009，7 patients with advanced GISTs were enrolled. They were treated with sunitinib 50mg daily for 4 weeks with 2-week interval，and 6 weeks was a cycle. Results One of the 7 patients withdrew from the study after 1 cycle treatment, and the median treatment duration of the other 6 patients was 7 cycles（2-22 cycles），the best response were all SD，the median progression-free survival was 9.0 months（2.5-29.5 months），and the median overall survival was 28 months（4.49 months）. All the patients experienced adverse events，mainly in grade 1-2. The common events included leukopenia，thrombocytopenia，diarrhea，microscopic hematuria，fatigue， and proteinuria. One patient experienced heart failure. Conclusion Malate sunitinib was effective and welltolerated for advanced GISTs as second-line treatment.